RxDoctor Payments Data

Sherwin Hariri, MD

Allergy · Beverly Hills, CANPI 1699955179

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,596 of the $16,455 with a category attached, or 82.6%. It is spread thinly across 41 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,376, 3.9 times the $876 reported in 2019.

$16,455in general payments, 2019–2025

Across 524 payments — averaging $31.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$2K
  • Circassia Inc.$2K
  • GSK$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Sanofi$1K
  • Octapharma USA, Inc.$1K
  • plus $7K from 35 others

What the payments were for

  • Consulting fees$340%
  • Speaking & faculty fees$2,75017%
  • Food & beverage$13,59683%
  • Education$750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,455 in reported general payments places this provider in the 85th percentile of 117 allergy providers in California.

See all allergy providers in California

Medicare billing

Part B allowed, 2024
$229,250
Medicare patients
324
Services billed
20,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab67$217,297
NucalaMepolizumab35$134,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,968
Cromolyn Sodium23$10,874
Epinephrine27$6,028
Azelastine Hcl35$736
Montelukast Sodium43$345
Fluticasone Propionate13$344
Albuterol Sulfate HfaAlbuterol Sulfate18$343
Levocetirizine Dihydrochloride35$178
Sodium Chloride0.9 % Sodium Chloride16$163
Famotidine16$142
Methylprednisolone14$108
Doxepin Hcl11$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$433$217,29767 claims
GSKNucala, Trelegy Ellipta$1,557$155,25964 claims
Hikma Pharmaceuticals USAEpinephrine$24$6,02827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 allergy providers in California.

Other allergy in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →